JPMorgan raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $60 from $57 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals to Present at Key Investor Conferences
- Xenon Pharmaceuticals’ Earnings Call Highlights Optimism and Progress
- Xenon Pharmaceuticals price target raised to $58 from $55 at RBC Capital
- Xenon Pharmaceuticals price target lowered to $44 from $48 at Wells Fargo
- Xenon Pharmaceuticals: Promising Drug Pipeline and Market Potential Drive Buy Rating